Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring

@article{Hunt2012NatalizumabassociatedPM,
  title={Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring},
  author={D. Hunt and G. Giovannoni},
  journal={Practical Neurology},
  year={2012},
  volume={12},
  pages={25 - 35}
}
  • D. Hunt, G. Giovannoni
  • Published 2012
  • Medicine, Computer Science
  • Practical Neurology
  • Natalizumab reduces relapse frequency, delays onset of disease progression and improves disease outcomes in relapsing–remitting multiple sclerosis (MS) and is a cost-effective treatment for rapidly evolving severe relapsing–remitting MS. However, it is associated with the development of progressive multifocal leucoencephalopathy (PML), a serious opportunistic brain infection caused by a neurotropic strain of the JC virus (JCV). Until May 2011, 83 300 patients had received natalizumab for MS… CONTINUE READING
    49 Citations
    Natalizumab to fingolimod washout in patients at risk of PML
    • 16
    • PDF
    New and Old Concepts and Strategies for Progressive Multifocal Leukoencephalopathy
    • 2
    • PDF
    Body weight-based natalizumab treatment in adult patients with multiple sclerosis
    • 19

    References

    SHOWING 1-10 OF 37 REFERENCES
    Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.
    • 768
    • PDF
    No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study
    • 36
    Progressive multifocal leukoencephalopathy after natalizumab monotherapy.
    • 212
    Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies.
    • E. Major
    • Biology, Medicine
    • Annual review of medicine
    • 2010
    • 422
    • PDF